SCHEMBL21705628

SCHEMBL21705628

CC(C)(C)OC(=O)Nc1csc(Br)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 5/20 0.41
PI4KB Q9UBF8 1/20 0.39
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
GSK3B P49841 1/20 0.38
DYRK1A Q13627 1/20 0.38
PSMB8 P28062 1/20 0.37
HDAC3 O15379 2/20 0.37
HDAC1 Q13547 2/20 0.37
HDAC2 Q92769 2/20 0.37
HDAC10 Q969S8 2/20 0.37
HDAC8 Q9BY41 2/20 0.37
METAP1 P53582 1/20 0.37
SCN9A Q15858 1/20 0.36
NPC1 O15118 1/20 0.36
RECQL P46063 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
SREBF2 Q12772 1/20 0.36
CYP17A1 P05093 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2600848 0.84 PI4KB (0.42) LCKPI4KBCA1CA2GSK3B
SCHEMBL20557380 0.83 PI4KB (0.39) LCKPI4KBCA1CA2GSK3B
SCHEMBL26678642 0.81 PI4KB (0.38) LCKPI4KBCA1CA2GSK3B
SCHEMBL22031128 0.80 CA1 (0.39) LCKPI4KBCA1CA2GSK3B
SCHEMBL22031127 0.80 CDK5 (0.44) LCKPI4KBCA1CA2GSK3B
SCHEMBL24044235 0.80 CDK5 (0.44) LCKPI4KBCA1CA2GSK3B
SCHEMBL28935820 0.80 GSK3B (0.38) LCKPI4KBCA1CA2GSK3B
SCHEMBL28935615 0.80 PI4KB (0.37) LCKPI4KBCA1CA2GSK3B
SCHEMBL9481637 0.79 GSK3B (0.37) LCKPI4KBCA1CA2GSK3B
SCHEMBL1796358 0.79 ABCB1 (0.38) LCKPI4KBCA1CA2GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4743081-A1 MODULATORS OF MITOCHONDRIAL DNA REPLICATION Pretzel Therapeutics, Inc. (US) 2026-05-20 EP disclosed
EP-4041730-B1 SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2026-05-13 EP disclosed
US-20250346585-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2025-11-13 US disclosed
US-12448395-B2 Substituted bicyclic heteroaryl compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2025-10-21 US disclosed
EP-4573088-A1 HETEROCYCLE RBM39 MODULATORS Recursion Pharmaceuticals, Inc. (US) 2025-06-25 EP disclosed
WO-2025045233-A1 MACROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF 劲方医药科技(上海)股份有限公司 2025-03-06 WO disclosed
CN-114761404-B Substituted bicyclic heteroaryl compounds 百时美施贵宝公司 2025-02-21 CN disclosed
WO-2025019407-A1 MODULATORS OF MITOCHONDRIAL DNA REPLICATION PRETZEL THERAPEUTICS, INC. (US) 2025-01-23 WO disclosed
US-20240124489-A1 SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2024-04-18 US disclosed
US-20240092770-A1 Heterocycle RMB39 Modulators RECURSION PHARMACEUTICALS, INC. 2024-03-21 US disclosed
WO-2024039689-A1 HETEROCYCLE RBM39 MODULATORS RECURSION PHARMACEUTICALS, INC. (US) 2024-02-22 WO disclosed
WO-2023183405-A2 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2023-09-28 WO disclosed
US-20230139171-A1 SYSTEM AND METHOD FOR INSTRUCTING ONE OR MORE WEATHER DRONES SITA INFORMATION NETWORKING COMPUTING UK LIMITED (GB) 2023-05-04 US disclosed
US-20230139171-A1 SYSTEM AND METHOD FOR INSTRUCTING ONE OR MORE WEATHER DRONES SITA INFORMATION NETWORKING COMPUTING UK LIMITED (GB) 2023-05-04 US disclosed
US-20230139171-A1 SYSTEM AND METHOD FOR INSTRUCTING ONE OR MORE WEATHER DRONES SITA INFORMATION NETWORKING COMPUTING UK LIMITED (GB) 2023-05-04 US disclosed
CN-115611895-A Arylamino derivative estrogen receptor modulators and uses thereof 四川海思科制药有限公司 2023-01-17 CN disclosed
EP-4041730-A1 SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS Bristol-Myers Squibb Company (US) 2022-08-17 EP disclosed
CN-114761404-A Substituted bicyclic heteroaryl compounds 百时美施贵宝公司 2022-07-15 CN disclosed
WO-2021067326-A1 SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2021-04-08 WO disclosed
WO-2020030924-A1 THIAZOLEUREAS AS ANTICANCER AGENTS ARTIOS PHARMA LIMITED (GB) 2020-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124489-A1 SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS TLR7, TLR1, TLR9 LCK 205/4885PI4KB 1819/4885CA1 4425/4885
US-20250346585-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS C5, C1S, C9 LCK 2160/4885PI4KB 2306/4885CA1 4723/4885
US-12448395-B2 Substituted bicyclic heteroaryl compounds TLR7, TLR1, TLR9 LCK 205/4885PI4KB 1819/4885CA1 4425/4885
US-20240092770-A1 Heterocycle RMB39 Modulators PRMT9, RCC2, RBBP9 LCK 2679/4885PI4KB 1368/4885CA1 4867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.